基础医学与临床 ›› 2010, Vol. 30 ›› Issue (2): 212-214.

• 短篇综述 • 上一篇    下一篇

非小细胞肺癌中K-RAS基因突变最新临床意义

付鲜花 黄建瑾   

  1. 浙江大学医学院附属第二医院
  • 收稿日期:2009-03-10 修回日期:2009-04-29 出版日期:2010-02-05 发布日期:2010-02-05

Research progresses on K-RAS mutation of non-small cell lung cancer

Xian-hua FU, Jian-jin HUANG   

  1. The Affiliated Second Hospital, School of Medicine, Zhejiang University
  • Received:2009-03-10 Revised:2009-04-29 Online:2010-02-05 Published:2010-02-05

摘要: 非小细胞肺癌(NCSLC)中15-30%有K-RAS突变,目前研究认为,其突变与表皮生长因子受体(EGFR)突变互相排斥,与EGFR酪氨酸激酶抑制剂(EGFR-TKIs)耐药正相关,但与C-225疗效无正相关关系,与NCSLC不良预后有关。现有许多研究探索法尼基转移酶抑制剂(Ftase抑制剂,FTIs)、RAF抑制剂、MAPK激酶(MEK)抑制剂来消除突变性K-RAS活性,改善临床疗效。

关键词: K-RAS, 非小细胞肺癌

Abstract: Mutated K-RAS can been observed among 15-30% NSCLC patients,the mutations of K-RAS and EGFR are mutually exclusive,K-RAS mutations have poor sensitivity to EGFR-TKIs,The response of C-225 is not restricted to mutated K-RAS , NSCLC patients with K-RAS mutations are associated with unfavorable prognosis.A number of different approaches such as Ftase inhibitors,RAF inhibitors,MEK inhibitors aimed at abrogating K-RAS activity to improve clinical response have been explored in clinical trials.

Key words: K-RAS, non-small cell cancer

中图分类号: